Matthew Riese, MD, PhD
Assistant Professor, Medicine (Hematology and Oncology) and Microbiology & Immunology; Associate Investigator, Blood Research Institute, BloodCenter of Wisconsin
TCR signal transduction and application to tumor immunology
PhD, Microbiology, Medical College of Wisconsin, 2002
MD, Medical College of Wisconsin, Medicine, 2004
Internal Medicine Residency, Brigham and Women's Hospital, Harvard Medical School, 2007
Hematology/Oncology Fellowship, University of Pennsylvania, 2010
Matthew Riese, MD, PhD, is an Assistant Professor of Medicine, in the Division of Hematology and Oncology, Department of Medicine at the Medical College of Wisconsin. Dr. Riese graduated with MD and PhD degrees from the Medical College of Wisconsin in 2004 and then completed an internship and residency in internal medicine at Brigham and Women’s Hospital at Harvard Medical School in Boston, Massachusetts. He went on to complete a fellowship in hematology/oncology at the University of Pennsylvania in Philadelphia, Pennsylvania. Dr. Riese is board certified in Internal Medicine and Medical Oncology. He has authored numerous manuscripts and maintains an active research lab focused on augmenting immune-based therapies in the treatment of malignancy. Dr. Riese is interested in investigating immune therapies for genitourinary cancers. He specializes in the treatment of genitourinary malignancies at Froedtert Hospital.
In the field of cancer immunotherapies, much attention has been devoted towards studying the optimal combination of inhibitory T cell surface receptors that can be targeted with to boost anti-tumor T cell activity. Research in the Riese lab focuses on the study of intracellular negative regulators of T cells that may serve as useful targets in cancer treatment. Specifically, the lab focuses on diacylglycerol kinase ζ (dgkζ), a protein that metabolizes the second messenger diacylglycerol (DAG), serving as an off switch for DAG-regulated signaling, including activation of Ras and PKCq. We have found that T cells deficient in dgkζ demonstrate enhanced T cell activity and tumor clearance, both in subcutaneous tumor models, and orthotopic models that utilize T cells engineered to express chimeric antigen receptors (CARs). Work on the lab focuses both on understanding the molecular changes that result from manipulation of dgkζ in T cells, and on translating the work to eventually permit study in human patients.
(Bajor DL, Mick R, Riese MJ, Huang AC, Sullivan B, Richman LP, Torigian DA, George SM, Stelekati E, Chen F, Melenhorst JJ, Lacey SF, Xu X, Wherry EJ, Gangadhar TC, Amaravadi RK, Schuchter LM, Vonderheide RH.) Oncoimmunology. 2018;7(10):e1468956.
(Newman DK, Fu G, McOlash L, Schauder D, Newman PJ, Cui W, Rao S, Johnson BD, Gershan JA, Riese MJ.) J Leukoc Biol. 2018 Nov;104(5):883-893.
Diacylglycerol kinase ζ (DGKζ) and Casitas b-lineage proto-oncogene b-deficient mice have similar functional outcomes in T cells but DGKζ-deficient mice have increased T cell activation and tumor clearance.
(Wesley EM, Xin G, McAllister D, Malarkannan S, Newman DK, Dwinell MB, Cui W, Johnson BD, Riese MJ.) Immunohorizons. 2018 Apr 01;2(4):107-118.
(Nanbakhsh A, Best B, Riese M, Rao S, Wang L, Medin J, Thakar MS, Malarkannan S.) J Vis Exp. 2018 01 15(131).
(Jing W, Gershan JA, Holzhauer S, Weber J, Palen K, McOlash L, Pulakanti K, Wesley E, Rao S, Johnson BD, Riese MJ.) Cancer Res. 2017 10 15;77(20):5676-5686.
(Raychaudhuri R, Riese MJ, Bylow K, Burfeind J, Mackinnon AC, Tolat PP, Iczkowski KA, Kilari D.) Clin Genitourin Cancer. 2017 10;15(5):e897-e901.
(Jing W, Gershan JA, Blitzer GC, Palen K, Weber J, McOlash L, Riese M, Johnson BD.) J Immunother Cancer. 2017;5:51.
(Frankel AE, Flaherty KT, Weiner GJ, Chen R, Azad NS, Pishvaian MJ, Thompson JA, Taylor MH, Mahadevan D, Lockhart AC, Vaishampayan UN, Berlin JD, Smith DC, Sarantopoulos J, Riese M, Saleh MN, Ahn C, Frenkel EP.) Oncologist. 2017 04;22(4):369-374.
(Riese MJ, Moon EK, Johnson BD, Albelda SM.) Front Cell Dev Biol. 2016;4:108.
(Rajasekaran K, Riese MJ, Rao S, Wang L, Thakar MS, Sentman CL, Malarkannan S.) Front Immunol. 2016;7:176.
(Newman DK, Fu G, Adams T, Cui W, Arumugam V, Bluemn T, Riese MJ.) Sci Signal. 2016 Mar 08;9(418):ra27.
(Arumugam V, Bluemn T, Wesley E, Schmidt AM, Kambayashi T, Malarkannan S, Riese MJ.) J Leukoc Biol. 2015 Nov;98(5):703-12.